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Non Small Cell Lung Cancer is a highly heterogeneous tumor. Histologic intratumor hetero-
geneity could be ‘major’, characterized by a single tumor showing two different histologic
types, and ‘minor’, due to at least 2 different growth patterns in the same tumor. Therefore, a
morphological heterogeneity could reflect an intratumor molecular heterogeneity. To date,
few data are reported in literature about molecular features of the mixed adenocarcinoma.
The aim of our study was to assess EGFR-mutations and ALK-rearrangements in different
intratumor subtypes and/or growth patterns in a series of mixed adenocarcinomas and ade-
nosquamous carcinomas.
Methods
590 Non Small Cell Lung Carcinomas tumor samples were revised in order to select mixed
adenocarcinomas with available tumor components. Finally, only 105 mixed adenocarcino-
mas and 17 adenosquamous carcinomas were included in the study for further analyses.
Two TMAs were built selecting the different intratumor histotypes. ALK-rearrangements
were detected through FISH and IHC, and EGFR-mutations were detected through IHC
and confirmed by RT-PCR.
PLOSONE | DOI:10.1371/journal.pone.0139264 September 30, 2015 1 / 15
OPEN ACCESS
Citation: Marino FZ, Liguori G, Aquino G, La Mantia
E, Bosari S, Ferrero S, et al. (2015) Intratumor
Heterogeneity of ALK-Rearrangements and
Homogeneity of EGFR-Mutations in Mixed Lung
Adenocarcinoma. PLoS ONE 10(9): e0139264.
doi:10.1371/journal.pone.0139264
Editor: Gianpaolo Papaccio, Second University of
Naples, ITALY
Received: July 23, 2015
Accepted: September 10, 2015
Published: September 30, 2015
Copyright: © 2015 Marino et al. This is an open
access article distributed under the terms of the
Creative Commons Attribution License, which permits
unrestricted use, distribution, and reproduction in any
medium, provided the original author and source are
credited.
Data Availability Statement: All relevant data are
within the paper.
Funding: The authors have no support or funding to
report.
Competing Interests: The authors have declared
that no competing interests exist.
Results
10/122 cases were ALK-rearranged and 7 from those 10 showing an intratumor heteroge-
neity of the rearrangements. 12/122 cases were EGFR-mutated, uniformly expressing the
EGFR-mutated protein in all histologic components.
Conclusion
Our data suggests that EGFR-mutations is generally homogeneously expressed. On the
contrary, ALK-rearrangement showed an intratumor heterogeneity in both mixed adenocar-
cinomas and adenosquamous carcinomas. The intratumor heterogeneity of ALK-rearrange-
ments could lead to a possible impact on the therapeutic responses and the disease
outcomes.
Introduction
Lung cancer represents a very heterogeneous tumor not only for its clinical and radiologic pre-
sentation but also for its histological and molecular features. Particularly, major histologic het-
erogeneity, characterized by a single tumor showing at least two different histologic types, and
minor histologic heterogeneity with a single tumor showing just one histologic type but at least
two different growth patterns, are generally recorded [1].
Adenocarcinoma (ADC) is the most frequently diagnosed histological type of primary lung
cancer accounting for almost half of all lung cancers [2]. Histologic intratumoral heterogeneity
in ADCs is expressed both in terms of a frequent minor heterogeneity due to the occurrence of
several growth patterns, such as lepidic, acinar, papillary, micropapillary and solid adenocarci-
noma in mixed adenocarcinomas (mADCs), and an unusual major heterogenity as in the ade-
nosquamous lung carcinomas (AdSqLCs). According to the 2004 World Health Organization
(WHO) classification, more than 80% of lung adenocarcinomas falls into the mixed subtype
[3].
In recent years, major revisions have been made to the classification and grading of ADCs,
leading to an improvement of the diagnosis of these tumors with a subsequent prognostic strat-
ification. Thus, the 2011 IASLC/ATS/ERS (International Association for the Study of Lung
Cancer/American Thoracic Society/European Respiratory Society) classification of lung adeno-
cacinomas has introduced some significant revisions to the 2004 WHO ADCs classification
[4]. In particular, a 5% increment in the comprehensive histologic subtyping of the different
patterns of mADCs is recommended, in order to determine the predominant pattern. Many
series have shown the clinicopathological relevance and the prognostic role of the 2011 IASLC/
ATS/ERS classification being the predominant pattern of adenocarcinoma related to different
prognosis [5]. Moreover, Sica et al. proposed a grading system based on the histologic subtyp-
ing of mADCs, providing a grading score based on the two main growth patterns [6]. This pat-
tern-based scoring system has proved to improve both mADCs subclassification and better
prognostic stratification [7].
In the past decade, the advancement on the treatment targeting mutated Epidermal
Growth Factor Receptor (EGFR) and Anaplastic Lymphoma Kinase (ALK) have changed con-
siderably the possibility of therapy for Non Small Cell Lung Cancer (NSCLC) patients. EGFR
gene most common and clinically relevant mutations, accounting for approximately 80–90%
of EGFR-mutated patients, occur in two hot spots in the tyrosine kinase (TK) domain: in-
frame deletions in exon 19 (most frequently E746-A750) and L858R missense mutation in
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exon 21 leading to a base substitution of arginine to leucine at residue 858. The NSCLCs
harboring these mutations are responsive to EGFR tyrosine inhibitors and kinase inhibitors
(TKIs) [8]. Moreover, in AdSqLCs, a relatively high frequency of EGFR mutations (mut-
EGFR) is described [9,10], thereby patients with AdSqLCs are treated as lung adenocarcinoma.
Although the presence of two different histological components in AdSqLCs, identical mut-
EGFR have been detected simultaneously in both components, suggesting that the adenocarci-
noma and squamous cell carcinoma have a possible clonal origin [9].
ALK gene rearrangements (ALK-R) have been detected in approximately 5–7% of all
NSCLCs, with enrichment in a selected NSCLCs according to the specific clinicopathological
features, such as ADC histotype, never/former light smoker (<10 packs/year), young and
EGFR/KRAS wild-type patients [11]. ALK-rearranged NSCLC patients are responsive to the
treatment with specific inhibitors.
Several studies reported that mut-EGFR and ALK-R, generally mutually exclusive, are fre-
quently associated with specific histological features within the framework of adenocarcinomas
[11].
In literature, the main histologic subtypes ascribed to mut-EGFR are lepidic or mixed sub-
type with lepidic component [12,13] and papillary and micropapillary [13,14]. ALK-R are
described in many ADC subtypes, including lepidic, papillary, micropapillary and acinar [15–
17]. However, ALK-R are more frequently associated to the solid growth pattern with signet
ring cell component and a mucinous cribriform pattern [16,18]. ALK-R are rarely described in
AdSqLCs [19]. The high rate of morphological heterogeneity in ADCs/AdSqLCs could reflect a
heterogeneous molecular profiling, suggesting differential predictive values with specific poten-
tial therapeutical approaches. Thus, the aim of the present study is to assess mut-EGFR, such
as E746-A750 deletions (del E746-A750) and L858R mutation (mut L858R), and ALK-R in the
different subtypes and/or growth patterns in a series of ADCs/AdSqLCs
Materials and Methods
Ethics Statement
Ethics Statement Patient accrual was conducted according to internal Review Board of the INT
Fondazione Pascale (Naples, Italy) (CEI 556/10 of 12/3/2010), the Fondazione IRCCS “Ca’
Granda”—Ospedale Maggiore Policlinico (Milan, Italy) (179/2013 of 19/3/2013) and the
AORN Vincenzo Monaldi(Naples, Italy). Written informed consent was obtained from all par-
ticipants to the study. The INT Fondazione Pascale, the Fondazione IRCCS “Ca’ Granda”—
Ospedale Maggiore Policlinico and the AORN Vincenzo Monaldi ethics committees specifi-
cally approved this study.
Patient Cohort
A series of 590 NSCLCs tumors from patients undergoing surgical resection between 2006 and
2011 at the Istituto Nazionale Tumori “Fondazione G Pascale”-IRCCS, Naples, the Fondazione
IRCCS “Ca’ Granda”—Ospedale Maggiore Policlinico, and the AORN Vincenzo Monaldi,
Naples were collected. Among the 590 NSCLCs, 443 were ADCs, 19 AdSqLCs and 128 squa-
mous cell carcinomas. Inclusion criteria for the present analysis were: i) a tumor size of at least
1 cm of the selected block, ii) a tumor showing at least 2 different histotypes or patterns of
growth, iii) amount of available material in order to core the tissue cylinders with a 1 mm
diameter for each different histotype or pattern in the sample. The following clinical and path-
ological parameters were evaluated for patients cohort: patient age at initial diagnosis, smoking
habits, histologic grade, tumor stage, tumor recurrence or distant metastasis.
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Histologic Evaluation
Sections of 4 μm thickness from each block (with a mean of 3 blocks per tumor) were obtained
and were stained with hematoxylin-eosin. All 590 cases were reviewed by two expert pulmo-
nary pathologists (R.F. and E.L.M.) in order to identify the AdSqLCs and the mADCs subtypes.
105 mADCs and 17 AdSqLCs have been selected, according to a tumor size of at least 1 cm
and the histologic criteria suggested by Cadioli et al [1],minor heterogeneity was recorded
when the tumor showed just 1 histotype but at least 2 different patterns as in mADC, whereas
major heterogeneity was considered present when a tumor presented at least 2 different histo-
types as in AdSqLCs. All cases were reviewed according to the new IASLC/ATS/ERS classifica-
tion that allows for five comprehensive histologic subtypes of lepidic, acinar, papillary, solid
and micropapillary patterns by a percentage of 5% increments to determine a predominant
pattern [4]. Finally,the grade of mADC has been redefined according to the pattern-based scor-
ing system proposed by Sica et al. [6].
TMAs building
Two tissue microarrays were built using 105 mADCs, 17 AdSqLCs and 8 non-neoplastic lung
tissue samples. All areas representative of each different histological pattern have been selected
on the H&E-stained slides for every single case. Tissue cylinders (1 mm diameter) as many as
the different selected histologic patterns were punched from each ‘donor’ tissue block and
brought into one recipient paraffin block (3×2.5 cm) using a semiautomated tissue arrayer
(Galileo TMA).
Immunohistochemistry Analysis for EGFRmutations L858R and
deletion E746-A750
Immunohistochemical staining was carried out on TMAs slides using EGFR mutation-specific
antibodies in order to identify L858R point mutation in exon 21 and E746_A750 deletion in
exon 19.
Paraffin slides was deparaffinized in xylene and rehydrated through graded alcohols. Anti-
gen retrieval was performed with slides heated in EDTA buffer (pH 9.0) in a bath for 20 min at
97°C. After antigen retrieval, the slides were allowed to cool. The slides were rinsed with TBS
and the endogenous peroxidase was inactivated with 3% hydrogen peroxide. After protein
block (BSA 5% in PBS 1×), the slides were incubated with monoclonal rabbit antibodies against
L858R mutation (dilution 1:100, clone 43B2 Cell Signaling Technology) and E746_A750
deletion (dilution 1:100, clone 6B6 Cell Signaling Technology) at 4°C overnight. The sections
were incubated with biotinylated anti-rabbit antibody for 40 minutes at room temperature.
Immunoreactivity was visualized by means of avidin-biotin-peroxidase complex kit reagents
(Novocastra, Newcastle, UK) as the chromogenic substrate. Finally, sections were weakly coun-
terstained with haematoxylin and mounted. As described in previous studies [20], the IHC
scoring was based on the cytoplasmic and/or membrane-staining intensity, as follows: no stain-
ing, score 0; weak staining in10% of tumor cells, score 1+; moderate staining in10% of
tumor cells, score 2+; strong staining in10% of tumor cells, score 3+. Furthermore, all cases
with IHC score 1+,2+,3+ were analyzed through molecular analysis to confirm mut-EGFR.
Real-time PCR for EGFRmutations L858R and deletion E746-A750
A real-time polymerase chain reaction (PCR)-based assay that uses mutant-specific probes
(EntroGen Inc USA), to identify the presence of EGFR mutations in exons 18,19,20 and 21.
Genomic DNA was extracted according to manufacturer’s protocol.
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Fluorescence in situ hybridization for ALK gene rearrangements
Fluorescence in situ hybridization (FISH) analysis was performed on unstained 5 μm thick
TMAs slides, to detect ALK-R. Deparaffinization of sections was carried out with two 10 min
immersions in bioclear, followed by three 3 min immersions in ethanol 100, 70 and 50%. The
slides were rinsed in distilled water and immersed in Vysis pretreatment solution (1 M sodium
thiocyanate) at 80°C for 10 min, and in protease solution (previously warmed to 37°C) for
10 min, washed with purified water, air-dried, and dehydrated in ascending grades of alcohol.
The used probe was the commercially available ALK probe (Vysis LSI ALK Dual Color, Break
Apart Rearrangement Probe; Abbott Molecular, Abbott Park, IL) consisting of two fluorescent
probes, one red and one green signal, flanking the ALK break point. Denaturation and hybrid-
ization of the tissue sections were performed using the Thermobrite system (Abbott Molecular
Inc. Des Plaines, IL): 75°C for 5 min for the denaturation process and 37°C for 17 hours for
the hybridization of the probes. The slides were then washed with 0.4X saline- sodium citrate
(SSC) solution at 70°C for 2 min and 2X SSC at room temperature for 3–5 min. Lastly, 10 μL of
DAPI was applied on the slides. The fluorescence signals were evaluated under epifluorescence
microscope (Olympus) and the image acquisition was done by CCDmicroscopy camera. FISH
for ALK locus rearrangements was considered positive in relation to two different patterns: (1)
the classic break-apart pattern with one fusion signal and two separated orange and green sig-
nals (a distance2 signal diameters between two signals); (2) the atypical pattern with a single
red signal without a corresponding green signal in addition to fused signals.[21] A sample was
considered positive if>15% of the cells counted out of minimum 60 in at least one tissue core
were positive.
Immunohistochemistry Analysis for ALK protein expression
Immunohistochemical staining was performed on 4 μm thick TMAs sections. Immunohis-
tochemistry (IHC) analysis was performer using the VENTANA anti-ALK (D5F3) Rabbit
Monoclonal Primary Antibody, used with the OptiView DAB IHC Detection Kit and OptiView
Amplification Kit (Ventana Medical Systems USA), as a fully automated assay on the Ventana
BenchMark XT processor. A binary scoring system (positive or negative for ALK status) was
adopted to evaluate the staining results, according to the manufacture’s scoring algorithm. The
samples were considered positive when tumor cells (any percentage of positive tumor cells)
showed a strong granular cytoplasmic staining.
Statistical Analysis
Pearson Χ-square test was performed to determine the association of clinical characteristics
with status of protein expression. Spearman rank test was used to assess the correlation
between protein phenotypes. The logrank test was used to compare survival distributions
between positive and negative staining groups. P< 0.05 (2-sided) was considered to be statisti-
cally significant. Data analysis and summarization were conducted using SPSS 20.0 for Mac
(SPSS Inc., Chicago, Ill).
Results
Clinical and Pathological Characteristics of patients
Among the 590 NSCLCs revised, 105 mADCs and 17 AdSqLCs were included in the present
analysis (Fig 1). Clinical and pathological features of 122 patients are shown in Table 1. 85 out
of 122 (69.7%) were male patients. The mean age was 64 years (range 44–82). 64 out of 87 were
current smokers. Among all patients, 53.2% were stage I, 24.6% stage II, 20.5% stage III, and
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1.6% stage IV. Of the 17 AdSqLCs, 10 were grade II, 6 grade III and 1 grade I. Using the grading
scheme proposed by Sica et al [6], of the 105 mADCs, 63 were grade III, 31 grade II and 11
grade I. The majority of the mADCs were composed of two histological patterns of growth
(71 cases, 67.6%), 26 cases (24.7%) of three patterns, 6 cases (5.7%) of four patterns and only
2 samples (1.9%) of more than four patterns. In most mADCs the predominant pattern was
the solid pattern (51cases, 48.6%), in 38 cases (36.2%) was the acinar pattern, followed by the
lepidic pattern (10 cases; 9.5%), papillary pattern (5 cases; 4.7%) and only 1 case with micropa-
pillary pattern.
Fig 1. Study Profile.NSCLC: Non Small Cell Lung Cancer; ADC:Adenocarcinoma; AdSqLC: Adenosquamous Lung carcinoma; SQ: Squamous Cell
carcinoma; mADCs: mixed adenocarcinomas; ALK-R: ALK-rearrangments.
doi:10.1371/journal.pone.0139264.g001
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Table 1. Clinical and pathological features of patients.
Characteristics No. of cases(%) mADCs AdSqLCs
All cases 122 105 17
Age, years
>64 y 64(52.4%) 56(53.3%) 8(47.1%)
<64 y 58(47.5%) 49 (46.6%) 9(52.9%)
Gender
male 85(69.7%) 74 (70.4%) 11(64.7%)
female 37(30.3%) 31(29.5%) 6(35.3%)
Smoking Status
Smoker 64(52.4%) 56(53.3%) 8(47.1%)
Never and/or Light Smoker 16(13.1%) 15(14.3%) 1(5.8%)
Ex-smoker 7(5.7%) 3(2.8%) 4(23.5%)
NA* 35(28.7%) 31(29.5%) 4(23.5%)
Disease stage
IA 33(27%) 31(29.5%) 2(11.8%)
IB 32(26.2%) 27(25.7%) 5(29.4%)
IIA 20(16.4%) 17(16.2%) 3(17.6%)
IIB 10(8.2%) 9(8.6%) 1(5.9%)
IIIA 25(20.5%) 19(18.1%) 6(35.3%)
IV 2(1.6%) 2(1.9%) -
Grade Sica score
I 12(9.8%) 11(10.5%) 1(5.8%)
II 41(33.6%) 31(29.5%) 10(58.8%)
III 69(56.5%) 63(60%) 6(35.3%)
ALK Status
ALK wt 112(91.8%) 98(93.3%) 14(88.2%)
ALK-R 10(8.2%) 7(6.6%) 3(17.6%)
EGFR Status
del ex 19 10(8.2%) 10(9.5%) -
L858R ex 21 2(1.6%) 2(1.9%) -















NA: not available; Wt: wild type, mADCs: mixed adenocarcinomas, AdSqLCs: adenosquamous lung carcinoma,ALK: Anaplastic Lymphoma Kinase,
EGFR: Epidermal Growth Factor Receptor.
doi:10.1371/journal.pone.0139264.t001
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EGFR Results
EGFR IHC and RT-PCR. 12/122 cases were EGFR-mutated: specifically, 10 cases carrying
del E746-A750 and 2 mut L858R. 10 cases positive by immunohistochemistry (IHC) were con-
firmed by Real time PCR, but no material was available for the other two cases. Clinical and
pathological features of the EGFR-mutated patients are shown in Table 2. 7 out of 12 patients
were females patients. The mean age of EGFR-mutated patients was 63.4 (range 49–78). 5
cases out of 12 were ex-smoker/nonsmokers, 3 current smokers and no smoking habits were
Table 2. Clinical and pathological features of patients harboring mut-EGFRand ALK-R.
Characteristics No, of cases mut-EGFR No, of cases ALK-R No, of cases ALK-R and mut- EGFR
All cases 12 10 2
Age, years
>64 y 6(50%) 7(70%) 2(10%)
<64 y 6(50%) 3(30%) 0
Gender
male 5(41.6%) 10(100%) 2(10%)
female 7(58.3%) 0 0
Smoking Status
Smoker 3(25%) 2(20%) 0
Never and/or Light Smoker 3(25%) 2(20%) 0
Ex-smoker 2(16.6%) 3(30%) 1(5%)
NA* 4(33.3%) 3(30%) 1(5%)
Disease stage
IA 3(25%) 3(30%) 0
IB 2(16.6%) 3(30%) 1(5%)
IIA 4(33.3%) 2(20%) 0
IIB 1(8.3%) 1(10%) 1(5%)
IIIA 2(16.6%) 1(10%) 0
IV 0 0 0
Grade
I 0 0 0
II 7(58.3%) 3(30%) 1(5%)
III 5(41.6%) 7(70%) 1(5%)
Subtype
mADCs 12(100%) 7(70%) 2(10%)
AdSqLC 0 3(30%) 0
No. of cases with heterogeneity 1(8.3%) 7(70%) 0 mut EGFR, 2 ALK-R,
No. of patterns with aberration
Acinar 11 4 2 mut EGFR, 0 ALK-R
Solid 7 9 2 mut EGFR, 2 ALK-R
Papillary 5 1 1 mut EGFR, 0 ALK-R
Lepidic 4 1 0 mut EGFR, 0 ALK-R
Mucinous 2 0 1 mut EGFR, 0 ALK-R
Signet-ring cell 2 1 1 mut EGFR, 1 ALK-R
Micropapillary 1 0 1 mut EGFR, 0 ALK-R
NA: not available; Wt: wild type, mADCs: mixed adenocarcinomas, AdSqLCs: adenosquamous lung carcinoma,ALK: Anaplastic Lymphoma Kinase,
EGFR: Epidermal Growth Factor Receptor.
doi:10.1371/journal.pone.0139264.t002
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available for 4 patients. Of the 12 EGFR-mutated cases, 7 were of 12 grade II and 5 of grade III.
Most EGFR positive cases were recorded in stage I (5/12) and stage II (5/12). The statistical
analysis showed no correlation between mut-EGFR and clinicopathological features of
patients.
Intratumoral homogeneity of EGFR mutations. All 12 EGFR-mutated cases were
mADCs and 11 out of 12 cases uniformly expressed the mutated receptor in all histologic pat-
terns, except case n. 8. The details are summarized in Table 3.
ALK Results
ALK FISH and Immunohistochemistry. 10 out of 122 (8.2%) cases were ALK-rearranged
cases identified through FISH. Clinical and pathological features of the ALK-rearranged
patients are shown in Table 2. All 10 patients were males with a mean age of 65.6 years (range
44–78). 5 cases out of 7 were ex-smokers/nonsmokers, 2 current smokers. Most ALK-rear-
ranged cases were grade III (7/10) and stage I (6/10). 2 out of 10 cases (samples 4 and 15) ALK-
rearranged showed the atypical FISH pattern. 9 out of 10 ALK-rearranged by FISH cases are
analyzed through IHC. Thus, 8 out of 9 ALK-rearranged through FISH cases were also positive
by IHC, while only 1 is ALK IHC negative. The statistical analysis showed a significant relation
between ALK-R and male gender (P value = 0.029). However, no statistical correlation between
ALK-R and another clinicopathological features of patients was present.
Intratumor heterogeneity of ALK-R. 7/10 ALK-rearranged cases were mADCs and 3/10
were AdSqLCs. Particularly, 7 out of 10 showed an intratumor heterogeneity relative to ALK-R
presence. In all cases, ALK negative cores showed a percentage of ALK-R in neoplastic cell
<5%. Thus, ALK-R in all 3 AdSqLCs were exclusively found in the adenocarcinoma compo-
nent and, in mADC, the solid pattern showed ALK-R more frequently than the other patterns
of growth, since 9 out of 10 ALK rearranged cases include solid growth pattern. The details of
the histologic patterns are summarized in Table 3. The solid pattern showed ALK-R more fre-
quently (9 out of 10 cases) than the others patterns of growth.
Patients with Concomitant ALK-R and del-ex19 EGFR
In our series, two males patients (samples 4 and 11, tab.2) had concomitant ALK-R and del
E746-A750. Both cases showed an intratumor heterogeneity of ALK-R, while a homogeneous
expression of del E746-A750 in all patterns was found. Clinical and pathological features are
shown in Table 3. The histological features of case 4 are shown in Fig 2.
Discussion
The intratumor heterogeneity in most human cancers is considered a great limitation for the
correct diagnosis, the prognostic stratification and a successful treatment of the disease. The
intratumor heterogeneity is the result of both the genetic disorders and the influence of the
tumor microenvironment, both potentially reflecting on a variability of morphological features
[22]. Thus, the balance of different tumor cells populations within the tumor should signifi-
cantly determine the tumor progression and the cell survival under adverse conditions of the
dynamic microenvironment and tumor resistance to specific treatment [23,24].
Recently, a multidisciplinary platform have radically systematized the characterization of
lung ADC on histological, radiological, clinical and molecular levels. Particularly, the predomi-
nant pattern of tumoral growth in mADC and molecular features driving biological treatment
have been greatly emphasized [4].
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Table 3. Clinical and Histological features of ALK-rearranged and EGFR-mutated patients.












1 M 49 IIIA YES III 5(3,2) solid NR - - 40% del
solid-signet NR - - 50% del
acinar NR - - 40% del
2 F 63 IIA NO II 4(1,3) lepidic NR - - 40% del
solid NR - - 50% del
acinar NR - - 40% del
3 F 52 IA NA* II 4 (2,2) acinar NR - 30% - mut L858R
papillary NR - 40% - mut L858R
lepidic NR - 30% - mut L858R
4 M 78 IB EX III 5 (3,2) solid R(30%) + - 30% del
solid-signet a R(20%) + - 40% del
micropapillary NR(<5%) - - 30% del
papillary NR(<5%) - - 30% del
acinar NR(<5%) - - 60% del
5 M 75 IB EX III AdSqLC solid-signet NR(<5%) - - - /
solid R(30%) + - - /
acinar NR(<5%) - - - /
squamous NR(<5%) - - - /
6 M 65 IB EX III AdSqLC acinar NR(<5%) - - - /
solid R(20%) + - - /
squamous NR(<5%) - - - /
7 F 52 IA EX II 3 (2,1) papillary NR - - 70% del
lepidic NR - - 70% del
8 F 66 IIA NO II 4(2,2) papillary NR - - - del
mucinous NR - - 40% del
acinar NR - - 50% del
9 M 67 IA NA* III 5 (3,2) solid R(20%) + - - /
acinar R(20%) + - - /
lepidic R(20%) + - - /
10 M 77 IA NA* III 5 (3,2) solid R(30%) + - - /
acinar R(20%) + - - /
11 M 77 IIB NA* II 5 (2,3) acinar NR(<5%) - - 30% del
mucinous NR(<5%) - - 10% del
solid R(30%) - - 20% del
12 M 68 IA NA* II 3 (2,1) acinar NR - 40% - mut L858R
lepidic NR - 30% - mut L858R
13 M 44 IIA NO II 5 (2,3) acinar R(30%) NA* - - /
solid R(20%) NA* - - /
papillary NR(<5%) NA* - - /
14 M 60 IA YES III AdSqLC solid R(20%) + - - /
squamous NR(<5%) - - - /
15 M 47 IIA NO II 4 (2,2) papillary a R(20%) + - - /
acinar a R(20%) + - - /
16 M 66 III YES III 5 (3,2) solid R(30%) + - - /
acinar NR(<5%) - - - /
17 F 66 IIA NA* III 5 (3,2) solid NR - - 30% NA*
(Continued)
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Although molecular characterization is crucial for the choice of specific therapeutic treat-
ment, according to our knowledge, only few studies have analyzed mut-EGFR and ALK-R in
series of mADC and/or AdSqLCs.
It has been proposed that lung adenocarcinoma development occurs from atypical adeno-
matous hyperplasia (AAH) through bronchioloalveolar (BAC), redefined as lepidic, and finally
invasive adenocarcinoma, being the solid pattern the less differentiated adenocarcinoma com-
ponent [25]. Furthermore, it has been reported that the solid subtype in invasive adenocarcino-
mas is an independent poor prognostic factor and negative predictor for adjuvant
chemotherapy. In addition, although mut-EGFR is not frequent in solid predominant lung ade-
nocarcinoma, EGFR-mutated adenocarcinomas with solid subtype have poor response to
EGFR TKIs [26].
Previous studies have demonstrated EGFR abnormalities, as mutations and gene copy gain,
in the progression of lung adenocarcinoma. In fact, multifocal lung adenocarcinomas with
AAH and BAC (lepidic) patterns develop at 3 to 5 weeks of age in transgenic mice expressing
the del E748-A752 mutant version of mouse EGFR driven by the surfactant protein C pro-
moter [27]. In addition, it has variously demonstrated that those mutations are early detected
in lung cancer development, such as in preinvasive lesions, whereas copy number gains are
later events associated with the invasive phenotype and advanced stages of disease [28,29].
Thus, in the microdissected BAC (lepidic) pattern, EGFR mutations were commonly found
[30]. Our data confirms these previous reports, as 11 out of 12 EGFR-mutated cases show a
homogeneous EGFR mutation pattern in all histological patterns. The homogeneous distribu-
tion of EGFR mutations in all adenocarcinoma patterns of growth supports the hypothesis that
they are an early genetic event, often associated to lepidic component.
In our series, mut-EGFR are more frequent in ADCs with acinar growth pattern (11 out of
12 EGFR-mutated cases). The response to EGFR-TKIs in homogeneous tumors is expected to
be good, whereas it should be unsatisfactory in heterogeneous tumors. In fact, Chen et al com-
pared 180 pairs of lung adenocarcinoma samples: primitive and node metastasis, primitive and
distant metastasis, multiple lung nodules and metachrounous lung adenocarcinomas. The
study concluded that EGFR mutational pattern heterogeneity frequency is relatively low, more
commonly observed in multiple lung tumors, and that 38,2% of heterogenous pattern patients
showed a variable tumor response to EGFR TKIs, with frequent development of EGFR resis-
tance [31]. In addition, it has been reported that the intratumor heterogeneity of mut-EGFR is
Table 3. (Continued)












acinar NR - - 10% NA*
18 F 61 IIA NO II 4 (2,2) acinar NR - - 30% NA*
papillary NR - - 10% NA*
19 F 66 IB YES III 5 (3,2) solid NR - - 40% del
acinar NR - - 10% del
20 M 63 IIIA YES III 5 (3,2) acinar NR - - 40% del
solid NR - - 30% del
papillary NR - - 40% del
NA*: not available; ALK: Anaplastic Lymphoma Kinase, EGFR: Epidermal Growth Factor Receptor, R: ALK-rearranged, a R: ALK-rearranged with atypical
FISH pattern.
(*1): % of neoplastic cells with ALK-R.
doi:10.1371/journal.pone.0139264.t003
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extremely rare, probably due to the use of less sensitive mut-EGFR detection assays [32,33]. In
our study, we confirm by using highly sensitive RT-PCR the presence of mut-EGFR, in the
cases identified through an immunohistochemical approach. Moreover, immunohistochemical
homogeneous expression of mut-EGFR suggests that they are generally driver mutations, being
present all over the tumor without clonal diversification. On the other hand, in our series,
ALK-R showed a different distribution in the several growth patterns of mADCs. Previous
studies have stated a relationship between ALK-R and the adenocarcinoma histotype, particu-
larly in ADC including solid growth pattern and solid signet-ring variant. The results of the
present study show an intratumor heterogeneity of ALK-R both in mADCs and AdSqLCs. In
fact, 7 out of 10 cases harboring ALK-R have shown a diversified intratumoral distribution.
Fig 2. Representative results of the different areas of a mADCwith coexistence of del E746-A750 EGFR and ALK-R (case 4). Tumoral area of
standard H&E slide with microphotographs of each single growth pattern is identified by different colored arrows/box. Acinar pattern: A, B, C, D. Papillary
pattern: E, F, G, H. Lepidic pattern: I, L, M, N. Solid pattern: O, P, Q, R. Solid-signet ring cell pattern: S, T, U, V. In the first column: Hematoxylin and Eosin
staining for each histological pattern (20X). In the second column: del E746-A750 EGFR immunopositivity in all patterns. (20X) The black arrows indicate the
positive staining: acinar (B), papillary (F), lepidic (L), solid (P), signet (T). In the third column: ALK IHC results, acinar (C), papillary (G) and lepidic (M) patterns
are negative; solid(Q) and solid-signet ring cell (U) patterns are positive, indicated by the black arrows. In the fourth column: ALK FISH results, acinar (D),
papillary(H) and lepidic(N) are negative; solid pattern (R) shows the classic break-apart pattern with one fusion signal and two separated orange and green
signals, indicated by the white arrows. Solid-signet ring cell pattern (V) shows the atypical FISH pattern with fused signals and one single red signal without a
corresponding green signal, indicated by the white arrows.
doi:10.1371/journal.pone.0139264.g002
ALK-Rearrangements in Mixed Lung Adenocarcinoma
PLOSONE | DOI:10.1371/journal.pone.0139264 September 30, 2015 12 / 15
Particularly, ALK-R are generally observed in solid patterns of mADCs and exclusively in the
adenocarcinoma areas of AdSqLCs. Furthermore, 9 out of 10 ALK-rearranged sample cases
showed the rearrangements in the solid component regardless of the other subtypes within the
tumor. Moreover, solid pattern being frequently included in high Sica grading, ALK-R is signif-
icantly related to high grade tumors, as previously reported [11]. In our series, heterogeneous
presence of ALK-R could suggest that the acquisition of this aberration is late during cancer
progression.
In this view, a possible different frequency of mut-EGFR and ALK-R related to the different
histologic subtype could suggest a different behavior of these driver mutations in ADC, partic-
ularly in lepidic and solid growth patterns.
In addition, in our series two cases were characterized by the concomitant presence of del
E746-A750 and ALK-R. The distribution of del E746-A750 were not restricted to specific pat-
terns, in contrast to ALK-R. Thus, in both cases, del E746-A750 EGFR was observed in all pat-
terns and ALK-R only in solid and signet ring cell component. Previous studies have reported
cases of concomitant EGFR mutation and ALK-R even with a low frequency [34–37]. In our
series, the cases carrying both alterations represent the 17% of EGFR-mutated and the 20% of
ALK-rearranged, underlying that in the context of mixed tumors the frequency of concomitant
mutations could be higher. Thus, regarding patients harboring both mutations, it could open
the possibility of different target therapeutic strategies.
In conclusion, our data show that the expression of ALK-R is heterogeneous compared to
mut-EGFR in mADC and AdSqLCs. The results of this study raise several important issues
regarding the intratumor heterogeneity of ALK-R such as the clinical and therapeutic implica-
tions, since different response to ALK inhibitors could be due to genetic heterogeneity, possibly
strictly related to ADC “morphologic mosaic”. Further studies are required in order to clarify
the causes and the significance of ALK-R intratumor heterogeneity.
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